Left ventricular scar and the acute hemodynamic effects of multivein and multipolar pacing in cardiac resynchronization by Jackson, Tom et al.
IJC Heart & Vasculature 19 (2018) 14–19
Contents lists available at ScienceDirect
IJC Heart & Vasculature
j ourna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/ i jc -hear t -and-vascu la tureLeft ventricular scar and the acute hemodynamic effects of multivein and
multipolar pacing in cardiac resynchronizationTom Jackson a,⁎, Radoslaw Lenarczyk b, Maciej Sterlinski c, Adam Sokal b, Darrell Francis d, Zachary Whinnett d,
Frederic Van Heuverswyn e, Marc Vanderheyden f, Joeri Heynens g, Berthold Stegemann g,
Richard Cornelussen g, Christopher Aldo Rinaldi a
a Department of Cardiology, Guy's & St. Thomas' Hospitals & King's College London, London, United Kingdom
b Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Zabrze, Poland
c Instytut Kardiologii, Klinika Choroby Wieńcowej, Warszawa, Poland
d National Heart and Lung Institute, Imperial College, London, United Kingdom
e Hartcentrum, Universitair Ziekenhuis Gent, Gent, Belgium
f Onze-Lieve-Vrouwziekenhuis Aalst, Aalst, Belgium
g Medtronic Inc., Bakken Research Centre, Maastricht, The NetherlandsAbbreviations: HF, heart failure; CRT, cardiac res
biventricular; MVP, multivein pacing; MPP, multipolar p
acute hemodynamic response; CMR-LGE, cardiac magn
enhancement; LBBB, left bundle branch block; ME
electrocardiogram; CMR, cardiac magnetic resonance;
interval.
⁎ Corresponding author at: Cardiovascular Imaging, 4t
Hospital, London SE1 7EH, United Kingdom.
E-mail address: Thomas.jackson@kcl.ac.uk (T. Jackson
https://doi.org/10.1016/j.ijcha.2018.03.006
2352-9067/© 2018 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 26 October 2017
Accepted 21 March 2018
Available online 10 April 2018Background:We sought to determine whether presence, amount and distribution of scar impacts the degree of
acute hemodynamic response (AHR) with multisite pacing.
Multi-vein pacing (MVP) or multipolar pacing (MPP) with a multi-electrode left ventricular (LV) lead may offer
benefits over conventional biventricular pacing in patients with myocardial scar.
Methods: In this multi-center study left bundle branch block patients underwent an hemodynamic pacing study
measuring LV dP/dtmax. Patients had cardiacmagnetic resonance scar imaging to assess the effect of scar presence,
amount and distribution on AHR.
Results: 24 patients (QRS 171± 20ms) completed the study (83%male). An ischemic etiology was present in 58%
and the mean scar volume was 6.0 ± 7.0%. Overall discounting scar, MPP and MVP showed no significant AHR
increase compared to an optimized “best BiV” (BestBiV) site. In aminority of patients (6/24) receiver-operator char-
acteristic analysis of scar volume (cut off 8.48%) predicted a small AHR improvement with MPP (sensitivity 83%,
specificity 94%) but not MVP. Patients with scar volume N 8.48% had a MPP-BestBiV of 3± 6.3% vs.−6.4± 7.7%
for those below the cutoff. There was a significant correlation between the difference in AHR and scar volume for
MPP-BestBiV (R=0.49, p=0.02) but not MVP-BestBiV(R=0.111, p=0.62). The multielectrode lead positioned
in scar predicted MPP AHR improvement (p=0.04).
Conclusions:Multisite pacing with MPP and MVP shows no AHR benefit in all-comers compared to optimized
BestBiV pacing. Therewas aminority of patientswith significant scar volume in relation to the LV site that exhibited
a small AHR improvement with MPP.
(Study identifier NCT01883141)
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. This is an open access article under1. Background
Current cardiac resynchronization therapy (CRT) produces clinical
improvement in approximately 70% of patients with systolic heart
failure (HF) and a broad QRS [1]. Multiple studies have attempted to
predict non-responders and to optimize CRT implantation [2,3]. Left
ventricular (LV) scar adversely effects CRT acute response [4], chronic
remodeling [5] clinical improvement and mortality [6]. Both total scar
volume and scar location at the site of LV stimulation are associated
withworse outcomes [6,7]. Cardiacmagnetic resonance late gadolinium
enhancement (CMR-LGE) can accurately quantify, categorize and assessthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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within scarred myocardial segments [6].
Multisite left ventricular pacing is a promising technique,whichmay
improve CRT response, particularly in patients with ischemic heart dis-
ease and LV scar. Such stimulation can be achieved either by introducing
a second LV lead i.e. multivein pacing (MVP) [8–11] or pacing frommul-
tiple poles of a quadripolar lead i.e. multipolar pacing (MPP) [12,13].
Both techniques have demonstrated improvement in acute hemody-
namic response (AHR) [10] and mid-term (3–12 months) remodeling
parameters in small single center series [8,14]. Others have failed to
show significant incremental benefit with multisite LV pacing compared
to standard CRT [9,15,16] and some studies have suggested the
additional benefit of multisite pacingmay be limited to ischemic patients
with myocardial scar [10,17].
The iSPOT study (Study identifier NCT01883141) was the first multi-
center clinical trial designed to test AHR to both MVP and MPP within
the same patients with left bundle branch block (LBBB) in a robust,
reproducible protocol [16]. The results of the study showed no benefit
of MPP compared to optimized BIV pacing in “all-comers” with LBBB.
All patients in the study underwent pre-implantation CMR-LGE imaging
to image myocardial scar burden and distribution.
We hypothesized that patients with a significant scar burden as
percentage of the total LV and with significant scar per segment at the
site of the implanted LV lead may stand to benefit from multisite
techniques. We investigated the relationship between CMR-LGE derived
scar volume and location with AHR between optimized conventional
biventricular and multisite pacing (MPP and MVP).
2. Methods
The iSPOT study is a prospective non-randomized study at 7 hospitals
in Europe and the Middle East (Israel) evaluating contractile function
(AHR) using positive LV dP/dtmax between an optimized BiV and multi-
site pacing protocols in LBBB patients indicated for CRT. Patients were
enrolled prospectively and served as their own control. The study was
approved by local ethics committees and all patients gave written
informed consent.
Patients recruitedmet inclusion criteria for CRT according to current
ESC/AHA guidelines. All subjects were required to have LBBB and stable
sinus rhythm. Patients had one baseline visit prior to the acute study
including standard CMR-LGE techniques to assess scar volume and
location.
An AHR study was performed from femoral arterial and venous
access sites. An LV catheter (Micro-Cath™, Millar, TX) measured LV
dP/dtmax using a trans-aortic approach. An occlusive coronary sinus
venogram was obtained to identify the target vessels for LV stimulation.
To perform MPP either a quadripolar LV pacing lead or a decapolar
catheter was deployed via the femoral vein targeting a posterolateral
vein. For MVP two coronary veins (one anterior and one posterior)
were cannulated with LV leads (Fig. 1). The LV lead positions in an ante-
rior to posterior orientationwere determinedby the implantingphysician
fromfluoroscopy in the left anterior oblique projection; the basal to apical
position was determined using the right anterior oblique fluoroscopy
parameterized by the LV length from the cardiac magnetic resonance
images. Following the acute procedure the patients either had immediate
CRT or CRT implantation occurred at a later date dependent on operator
preference.
The following LV pacing configurations were evaluated:
1. Biventricular pacing with LV pacing from the distal electrode of the
multielectrode lead (MEL-dis)
2. Biventricular pacingwith LVpacing from themid electrode (MEL-mid)
3. Biventricular pacing with LV pacing from the proximal electrode
(MEL-prox)
4. MPP with LV pacing simultaneously from all three electrodes of the
MEL.5. Biventricular pacingwith LV pacing from or via the anterior vein lead
6. Biventricular pacing with LV pacing from or via the posterior vein
lead
7. MVP with LV pacing from anterior and posterior leads.
Allmeasurementswere compared to baseline atrial pacing at 100 bpm.
For all configurations a ventricular-ventricular delay of zero was used.
Each configuration was performed with 5 different atrio-ventricular
delays: the patient specific optimal atrio-ventricular delay derived from
the CardioSync™ algorithm, as well as at ±20 ms and ±40 ms. Each
pacing configuration and atrio-ventricular delay was repeated a
minimum of 4 times to reduce variance and increase signal to noise
ratio. Each pacing configuration was performed for ≥20 beats, and inter-
spersed with baseline AAI pacing (Fig. 1). The mean change in dP/dtmax
from AAI pacing was the primary outcome.
Scar volume and locationwas calculated using CMR42 (Circle Cardio-
vascular Imaging Inc., Calgary, Canada) from CMR-LGE short axis stacks
by segmenting endocardial and epicardial borders and applying a user-
defined high pass signal filter to highlight scarred regions. Scar volume
was calculated as percentage of totalmyocardialmass and per segment.
A scar volume ≥ 10% per American Heart Association segmentwas used
as a threshold for the lead in or adjacent to scar analysis. Adjacent to
scarwas lead placement in any segment surrounding a scarred segment
and lead placement distant to scar was where it was neither in nor
adjacent to scar. Scar volume using CMR-LGE was assessed at a single
core lab blinded to the AHR results.
All the study participants and implanters were blinded to analysis of
AHR data, which was performed offline (RC). The techniques used to
analyze the AHR data have previously been described [16]. The best im-
provement inmeanAHRwith BiV pacing (BestBiV)was subtracted from
the mean AHR to MPP to test for improvement with the MPP protocol
(MPP-BestBiV); this was repeated for theMVP protocol (MVP-BestBiV).
Further analyses were undertaken where the best BiV AHR from the
MEL was subtracted from the mean MPP AHR (MPP-BestBiV(MEL))
and where the best BiV from either the anterior or posterior leads was
subtracted from the mean MVP AHR (MVP-BestBiV(MVL)) in order to
directly test thepotential AHR advantagewith the advanced pacing tech-
niques from BestBiV using only the leads used within these protocols.
Statistical analysis was performed on PASW Statistics 21 (SPSS Inc.,
Chicago, IL, USA). The Kolmogorov-Smirnov one-sample test was used
to ensure variables were normally distributed. Continuous variables
were expressed as mean ± SD. Group comparisons were performed
using an independent-samples t-test for normally distributed data, and
the Mann-Whitney U test if non-parametric. Nominal variables were
expressed as absolute count and percentages and comparedwith Fisher's
exact test. Scar volumewas assessed using receiver-operator characteris-
tic analysis for additional benefitwithmulti-site pacing. Values of p b 0.05
were considered statistically significant.
3. Results
A total of 31 patients were enrolled in 7 separate cardiac centers.
Seven patients were excluded due to difficulties in completing the
protocol [16]. The characteristics of the remaining 24 patients with full
datasets are shown in Table 1. All patients had CMR-LGE available.
Fourteen patients had ≥10% scar in one or more segments, 10 patients
had no detectable scar. The total scar volume for the entire cohort was
6.0 ± 7.0%. The total scar volume in patients with scar was 9.5 ± 7.3%.
TheMELwas placed in the posterolateral (50%), anterolateral (4%) or
lateral vein (46%).MVPwas not possible in 1 patient; in the remaining 23
patients the “anterior” leadwas positioned in an anterior vein in 91% and
an anterolateral vein in 9%with the “posterior” lead in a posterior vein in
48%, a posterolateral vein in 39% and a lateral vein for the remaining 13%.
The right ventricular electrode was placed in the right ventricular apex
(63.3%) and right ventricular septum (36.7%).
Fig. 1. Scatter diagrams of A)MPP-BBVAHR (x axis) vs. Scar burden (%) and B)MPP–BBVAHR fromonlymultielectrode (MEL) electrodes vs. Scar burden (%)with lines of fit and 95%CIs. C)
ROC curve for any improvement with multipolar pacing (MPP) over best BiV pacing. D) Box and whisker plot for difference betweenMPP and best BiV AHR in the presence or absence of
significant scar. E) ROC curve for any improvement with multivein pacing over (MVP) best BiV pacing. F) Box and whisker plot for difference between MVP and best BiV AHR in the
presence or absence of significant scar.
Table 1
Demographic data of the cohort.
Patient demographics Total subjects (N = 24)
Gender Male 20 (83%)
Female 4 (17%)
Age (years) 61.5 ± 13.4
LVEF (%) 24.6 ± 6.4
NYHA class II 9 (38%)
III 15 (62%)
Etiology Ischemic 14 (58%)
Non-Ischemic 10 (42%)
QRS duration (ms) 171.4 ± 21.0
Mean scar burden (%) 6.0 ± 7.0
Values are total numbers (percentage) and mean± standard deviation. LVEF – left ven-
tricular ejection fraction, NYHA – New York Heart Association.
16 T. Jackson et al. / IJC Heart & Vasculature 19 (2018) 14–19Overall AHR in the MPP cohort was 31.4 ± 16.3%. The majority of
patients (75%) did not improve with MPP (i.e. MPP-BestBiV ≤ 0%,
mean−6.7 ± 7.5%). Only aminority of patients (N= 6, 25%) improved
with MPP (i.e. MPP-BestBiVN0%). The additional increase AHR in these
patients was 3.9 ± 5.3% (range 0.2–11.7%).
There was a significant correlation between scar volume and
MPP-BestBiV (R = 0.49, p = 0.02); undertaking this analysis with
MPP-BestBiV(MEL) improved this correlation (R = 0.55, p b 0.01,
Fig. 1) altering the BestBiV in 6 patients. Receiver-operator characteristic
analysis of scar volume for any improvement in MPP-BestBiV generated
an area under the curve (AUC) of 0.88. Scar volume of 8.48% had a sensi-
tivity of 83% and specificity of 94%. Patients with a scar volume greater
than this value had an MPP-BestBiV of 3 ± 6.3% vs. −6.4 ± 7.7% for
those with a scar volume below the cutoff (p b 0.01, Fig. 1).
BiV pacing from themultielectrode leadwas tested againstMPPwhen
the LV pacing site was within or outside scar; there was no significant
17T. Jackson et al. / IJC Heart & Vasculature 19 (2018) 14–19difference for each electrode (Table 2). In order to test if proximity of scar
was influential this analysis was repeated for whether the LV electrode
was in or adjacent to scar vs. distant to scar (Table 2). The presence of
any LV pacing electrode within scar was compared against a positive
improvement to MPP. For the MPP protocol 57% of patients with LV pac-
ingwithin scar improved as opposed to 12%where LV pacingwas outside
scar (p=0.04). If the electrodeswere assessed to be in or adjacent to scar
this was 50% vs. 7% (p=0.05) (Table 3).
Overall AHR improvement withMVPwas 30.8± 16.5%. Themajority
of patients (83%) did not improve with MVP (i.e. MVP-BestBiV ≤ 0%,
mean−26.9 ± 7.6%). Only aminority of patients (N= 4, 17%) improved
with MVP (i.e. MVP-BestBiVN0%). The additional increase AHR in these
patients was 8.3± 5.6% (range 2.1–14.4%).
There was no significant correlation between MVP-BestBiV and scar
volume (R = 0.111, p = 0.62); repeating this analysis only using the
BestBiV AHR from the multivein leads (i.e. the anterior and posterior
leads only) did not improve this correlation (R=−0.134, p = 0.542).
Receiver operator characteristic analysis of scar volume for any
improvement in MVP-BestBiV generated an AUC of 0.539. The scar
volume of 8.48% had a sensitivity of 50% and specificity of 79%. There
was no difference inMVP-BestBiV between thosewith orwithout signif-
icant scar (−4.4± 10.9% vs−7.4± 10.0% p= 0.54, Fig. 1). Therewas no
significant difference in MVP-BiV for individual pacing protocols where
the LV electrode was within or in/adjacent to scar compared to outside
scar (Table 2).
The distribution of scar was similar between the AHR improvers to
MPP and MVP, with the scar burden predominantly being located
posterolaterally and apically.
The QRS duration of those patients where MPP improved AHR was
167 ± 15 ms vs. 176 ± 21 ms for those who did not (p = 0.33).
Where MVP augmented AHR the QRS duration was 182 ± 11 ms vs.
174 ± 18ms (p= 0.39).
4. Discussion
This the first multicenter study to assess AHR to multisite CRT deliv-
ered via multivein and multipolar pacing in the same patient cohort and
using cardiacmagnetic resonance to characterize the effect ofmyocardial
scar on both.
The key findings are that within our cohort of LBBB patients:
1) The majority of patients fulfilling CRT criteria with LBBB failed
to show incremental AHR with multisite (multipolar or multivein)
pacing versus hemodynamically optimized BIV pacing.
2) Total LV scar volume may impact on improvement from MPP;
patients with scar on MRI were likely to have incremental hemody-
namic benefit with MPP.Table 2
Multipolar pacing and multivein pacing improvement dependent on spatial relationship of left
In scar Outside Scar p-Value
MPP
Distal 2.8 ± 5.6 0.8 ± 8.4 0.6
Mid 4.8 ± 7.2 2.1 ± 7.6 0.45
Proximal 4.9 ± 8.3 1.0 ± 3.9 0.13
MVP
Distal −2.4 ± 12.1 1.4 ± 20.7 1.0
Mid 0.03 ± 9.7 1.1 ± 14.5 0.61
Proximal 3.0 ± 6.6 −0.6 ± 16.0 0.60
Anterior lead 1.7 ± 2.5 10.1 ± 12.5 0.08
Posterior lead −0.4 ± 8.4 1.8 ± 5.2 0.46
Top panel - difference in AHR with multipolar pacing and BiV pacing from the multielectrode l
Bottom panel - difference in AHRwithmultivein pacing and BiV pacing from themultielectrode
Values are mean± SD (%).3) The presence of scar at or adjacent to the MEL increased the likeli-
hood of MPP response.
4) Scar volume and distribution had no impact on the likelihood of im-
provement fromMVP.
The results of themain iSPOT study showed that multisite pacing of-
fered no significant improvement in AHR in LBBB patients compared to
optimized standard CRT. The current results would suggest that in a
small sub-group of patients with significant myocardial scar there may
be incremental benefit [16]. In this analysis only 25% of patients gained
additional benefit from MPP and 17% with MVP. These improvement
rates are considerably less than other published data [12,13]. The AHR
benefit was minimal with a mean additional AHR amongst those who
improved of 3.9 ± 5.3% for MPP. This degree of additional benefit is in
keeping with previous AHR studies [12,15] and also within biophysical
models ofmultisite pacing [18]. The lower positive response tomultisite
pacing is likely to be driven by the inclusion criteria as all patients had
LBBB (mean QRS duration 171.4 ± 21.0 ms). This is in keeping with a
recent publication by Sohal et al. demonstrating a beneficial effect of
multisite pacing in only 7 of 16 patients, notably patients with strict
LBBB had no additional benefit [17]. The low response to multisite pac-
ing in this study is important as the study used rigorousmethodology to
ensure that standard BIV stimulationwas optimizedwith programming
of the atrio-ventricular delay and by repeated measures of AHR [16].
The failure of multisite pacing to enhance AHR over optimized conven-
tional CRT is in agreement with Padeletti et al. [9] who demonstrated
little added benefit when atrio-ventricular delays were optimized in
12 patients, 7 of whom were ischemic. The current findings also agree
with a recent canine study which demonstrated in a LBBB model that
additional pacing sites (up to 7) did not improve AHR if the initial site
was optimal [19].
This is the first study to report the impact of LV scar volume on AHR
with both MVP andMPP in the same patients. Of interest is the positive
effects seen in the presence of scar with MPP but not the MVP group.
This is in keeping with the findings of Pappone et al. [13] in 44 patients
where “multipoint” pacing in the 45% with ischemic cardiomyopathy
was as effective as in non-ischemic patients, despite a poorer response
to conventional BiV pacing. The difference in the two modalities may
be explained when considering the incremental benefit that each adds
to best BiV. TheMEL is targeted to the posterolateral wall, which is gen-
erally considered to the optimal position in LBBB. The BestBiV is most
likely to be as close to theposterolateralwall where scar is either absent,
or has the lowest impact on activation. The addition of a second pacing
point in a distant vein, which is more likely to be in scar if total scar vol-
ume is greater, is unlikely to add benefit. However, the addition of a sec-
ond posterolateral pacing point in the presence of scar has a greater
chance of adding incremental benefit on top of the best BiV pacingventricular lead and scar.
In or adjacent to scar Distant from scar p-Value
2.4 ± 5.0 0.7 ± 9.0 0.63
4.4 ± 6.4 1.7 ± 8.1 0.42
4.1 ± 7.4 0.6 ± 3.3 0.18
−2.0 ± 10.2 1.7 ± 22.4 0.67
−1.4 ± 8.4 2.3 ± 15.8 0.92
−1.7 ± 9.3 1.6 ± 16.7 0.59
6.5 ± 7.6 10.0 ± 14.0 0.73
−0.5 ± 7.3 2.4 ± 5.2 0.30
ead dichotomized by LV pacing site in scar and in or adjacent to scar.
lead andmultivein leads dichotomized by LV pacing site in scar and in or adjacent to scar.
Table 3
Bivariate comparisons of spatial relationship of scar and left ventricular lead with multipolar or multivein pacing improvement.
Lead(s) outside scar Lead(s) in scar p-Value Lead(s) distant from scar Lead(s) in or adjacent to scar p-Value
No multipolar improvement 15 (88%) 3 (43%) p = 0.04 13 (93%) 5 (50%) p = 0.05
Multipolar improvement 2 (12%) 4 (57%) 1 (7%) 5 (50%)
OR 10, 95% CI 1.2–81.8 OR 13, 95% CI 1.2–140.7
No Multivein Improvement 13 (87%) 6 (75%) p = 0.59 9 (82%) 10 (83%) p = 1.0
Multivein Improvement 2 (13%) 2 (25%) 2 (18%) 2 (17%)
OR 2.2, 95% CI 0.2–19.3 OR 0.9, 95% CI 0.1–7.8
Values are N (% of patients within each scar group). OR – odds ratio, CI – confidence interval.
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MVP does not seem to confer benefit is in keeping with Behar et al. who
recently demonstrated poor long-term results, especially concerning
device longevity, with this strategy [20].
MPP benefit from within scar was previously predicted by Niederer
et al. in a biophysical model withminimal dP/dtmax improvement in the
absence of scar but a 4.4% improvementwith dense scarmodelled in the
posterolateral wall [18]. This degree of AHR improvement is strikingly
similar to that seen in this study. The potential mechanism of benefit
may be that the scarred region has viable but slow conduction andmul-
tisite pacingmay pre-excite the region bringing forward the contraction
in the cardiac cycle. Two areas activated close to one another may
increase the volume of activation thereby coordinating the activation
to a greater extent. This is in keeping with a recent study by Umar et al.
who deliberately deployed a MEL straddling LV free wall scar and
compared AHR of MPP with conventional CRT in 16 patients [21]. In
this study 8 patients acutely responded to CRT, with the optimal settings
being MPP in 5 and apical LV lead placement of conventional CRT in 3.
5. Study limitations
The main study limitation is low sample size, albeit relatively large
for studies which are similarly invasive. The predictive scar value of
8.48% is both derived and tested within the same cohort and a prospec-
tive study is needed to corroborate this result. All patients fulfilled
stringent criteria for LBBB and are therefore likely to respond well to
BiV pacing; assessing for AHR beyond this is challenging. A further
study investigating these findings amongst right bundle branch block
and interventricular conduction delay patients is indicated. Finally, it
is uncertain that invasive dP/dtmax improvement confers long term
prognostic benefit, however it is currently the foremost acute response
metric available.
6. Conclusions
In conclusion multisite pacing with MPP and MVP shows no AHR
benefit in all-comers compared to optimized BestBiV pacing. However,
there was a minority of patients (25%) with significant scar volume, es-
pecially at the LV pacing site, that exhibited a small AHR improvement
(3.9 ± 5.3%) with MPP. There is a significant correlation between left
ventricular scar volume and improvement with multipolar LV pacing
from a single multipolar lead, however anterior-posterior multivein
pacing does not confer the same benefit in patients with scar.
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